The influences of Cinobufacin Capsules combined with XELOX regimen for neoadjuvant chemotherapy on therapeutic effects and prognosis in the treatment of locally advanced rectal cancer
ZHANG Zhi-yan
Department of Oncology, Songzi Hospital of Traditional Chinese Medicine of Jingzhou City, Hubei Province, Songzi 434200, China
Abstract：Objective To explore the influences of Cinobufacin Capsules combined with Capecitabine plus Oxaliplatin(XELOX) regimen for neoadjuvant chemotherapy on therapeutic effects and prognosis in the treatment of locally advanced rectal cancer. Methods A total of 72 patients with rectal cancer admitted to Songzi Hospital of Traditional Chinese Medicine from March 2013 to March 2015 were selected as the research objects, they were divided into the study group and the control group according to the random number table method, with 36 cases in each group. The control group received neoadjuvant chemotherapy with XELOX regimen, and the study group received Cinobufacin capsules combined with XELOX regimen. Three weeks as one treatment course, both groups were treated for 2 courses.The clinical efficacy, survival rate, quality of life and adverse reactions were compared between the two groups. Results The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P<0.05). The disease control rate of the study group was higher than that of the control group, and the difference was statistically significant (P<0.05). There was no significant difference in 1-year survival rate between the two groups (P>0.05); the 2-year and 3-year survival rates in the study group were higher than those in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the quality of life score between the two groups before treatment(P>0.05);the quality of life scores of the two groups at 1 and 3 months after treatment were higher than those before treatment of this group, the quality of life scores at 3 months after treatment were higher than those at 1 month after treatment in both groups, and the quality of life score of the study group was higher than that of the control group 1 and 3 months after treatment, and the differences were statistically significant(P<0.05). There was no significant difference in the adverse reactions between the two groups (P>0.05). Conclusion Cinobufacin Capsules combined with XELOX regimen for neoadjuvant chemotherapy in the treatment of locally advanced rectal cancer can significantly improve the total effective rate of clinical treatment and disease control rate, prolong the survival time of patients, improve their quality of life, at the same time, it does not increase adverse reactions.
张芝艳. 华蟾素胶囊联合XELOX化疗对局部晚期直肠癌患者疗效及预后生存的影响[J]. 中国当代医药, 2021, 28(21): 29-32.
ZHANG Zhi-yan. The influences of Cinobufacin Capsules combined with XELOX regimen for neoadjuvant chemotherapy on therapeutic effects and prognosis in the treatment of locally advanced rectal cancer. 中国当代医药, 2021, 28(21): 29-32.
Soda H，Maeda H，Hasegawa J，et al.Multicenter Phase Ⅱstudy of FOLFOX or biweekly XELOX and Erbitux（cetuximab）as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer：The FLEET study[J].Bmc Cancer，2015，15（1）：695.
京公网安备 11010502046607号